Related references
Note: Only part of the references are listed.Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
A. Bardia et al.
ANNALS OF ONCOLOGY (2021)
Novel antibody-drug conjugates for triple negative breast cancer
Aiko Nagayama et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Randomized Open Labe Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
In Hae Park et al.
CANCER RESEARCH AND TREATMENT (2019)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Targeting Trop-2 in solid tumors: future prospects
Saif Zaman et al.
ONCOTARGETS AND THERAPY (2019)
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan
David M. Goldenberg et al.
MABS (2019)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso et al.
BREAST (2017)
Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
X. Pivot et al.
ANNALS OF ONCOLOGY (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
Thomas M. Cardillo et al.
BIOCONJUGATE CHEMISTRY (2015)
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Robert M. Sharkey et al.
CLINICAL CANCER RESEARCH (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
Chris Twelves et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
The Management of Early-Stage and Metastatic Triple-Negative Breast Cancer: A Review
Carey K. Anders et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial
Adam Brufsky et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
Thomas M. Cardillo et al.
CLINICAL CANCER RESEARCH (2011)
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
Edith A. Perez et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy
Sung-Ju Moon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)